Cargando…
Maintenance therapy with histamine plus IL-2 induces a striking expansion of two CD56(bright) NK cell subpopulations in patients with acute myeloid leukemia and supports their activation
Histamine dihydrochloride (HDC) plus IL-2 has been proposed as a novel maintenance-immunotherapy in acute myeloid leukemia (AML). We analyzed the immunophenotype and function of natural killer (NK) cells in blood of AML patients treated after chemotherapy with HDC plus IL-2. The treatment caused a s...
Autores principales: | Cuapio, Angélica, Post, Mirte, Cerny-Reiterer, Sabine, Gleixner, Karoline V., Stefanzl, Gabriele, Basilio, Jose, Herndlhofer, Susanne, Sperr, Wolfgang R., Brons, Nicolaas H.C., Casanova, Emilio, Zimmer, Jacques, Valent, Peter, Hofer, Erhard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216810/ https://www.ncbi.nlm.nih.gov/pubmed/27341131 http://dx.doi.org/10.18632/oncotarget.10191 |
Ejemplares similares
-
Identification of heat shock protein 32 (Hsp32) as a novel target in acute lymphoblastic leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014) -
In vitro effects of histamine receptor 1 antagonists on proliferation and histamine release in canine neoplastic mast cells
por: Gamperl, Susanne, et al.
Publicado: (2020) -
Long-term treatment with imatinib results in profound mast cell deficiency in Ph+ chronic myeloid leukemia
por: Cerny-Reiterer, Sabine, et al.
Publicado: (2014) -
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1(T315I)+ clones in TKI-resistant CML
por: Schneeweiss-Gleixner, Mathias, et al.
Publicado: (2019) -
N‐terminal pro‐brain natriuretic peptide is a prognostic marker for response to intensive chemotherapy, early death, and overall survival in acute myeloid leukemia
por: Graf, Irene, et al.
Publicado: (2023)